May cause mild digestive upset in some users
Mizokami T, Wu Li A, El-Kaissi S, Wall JR
Read the full BPC-157 clinical overview BPC-157 vs TB-500: Comparison Side-by-side comparison of two leading healing peptides: mechanisms, indications, and how they are used together
What makes this mask special
A cohort study of moderate and severe head injury patients found that 67% of the cerebrolysin group achieved good outcomes (GOS 3-5) at 6 months, compared favorably to historical controls matched for age, sex, and initial severity
While many fear unknown side effects, the research highlights specific areas of concern and areas where the peptides are surprisingly safe